Insmed Statistics
Total Valuation
Insmed has a market cap or net worth of $29.13 billion. The enterprise value is $28.45 billion.
Important Dates
The next confirmed earnings date is Thursday, May 7, 2026, before market open.
| Earnings Date | May 7, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Insmed has 215.85 million shares outstanding. The number of shares has increased by 21.32% in one year.
| Current Share Class | 215.85M |
| Shares Outstanding | 215.85M |
| Shares Change (YoY) | +21.32% |
| Shares Change (QoQ) | +0.89% |
| Owned by Insiders (%) | 0.62% |
| Owned by Institutions (%) | 90.66% |
| Float | 193.49M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 48.03 |
| Forward PS | 16.77 |
| PB Ratio | 39.12 |
| P/TBV Ratio | 55.14 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 46.91 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.83, with a Debt / Equity ratio of 1.01.
| Current Ratio | 3.83 |
| Quick Ratio | 3.35 |
| Debt / Equity | 1.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -11.87 |
Financial Efficiency
Return on equity (ROE) is -249.28% and return on invested capital (ROIC) is -40.32%.
| Return on Equity (ROE) | -249.28% |
| Return on Assets (ROA) | -28.99% |
| Return on Invested Capital (ROIC) | -40.32% |
| Return on Capital Employed (ROCE) | -55.40% |
| Weighted Average Cost of Capital (WACC) | 10.27% |
| Revenue Per Employee | $364,437 |
| Profits Per Employee | -$767,293 |
| Employee Count | 1,664 |
| Asset Turnover | 0.28 |
| Inventory Turnover | 1.07 |
Taxes
In the past 12 months, Insmed has paid $5.03 million in taxes.
| Income Tax | 5.03M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +93.63% in the last 52 weeks. The beta is 1.10, so Insmed's price volatility has been higher than the market average.
| Beta (5Y) | 1.10 |
| 52-Week Price Change | +93.63% |
| 50-Day Moving Average | 148.47 |
| 200-Day Moving Average | 154.82 |
| Relative Strength Index (RSI) | 35.72 |
| Average Volume (20 Days) | 1,936,259 |
Short Selling Information
The latest short interest is 13.86 million, so 6.42% of the outstanding shares have been sold short.
| Short Interest | 13.86M |
| Short Previous Month | 13.76M |
| Short % of Shares Out | 6.42% |
| Short % of Float | 7.16% |
| Short Ratio (days to cover) | 5.41 |
Income Statement
In the last 12 months, Insmed had revenue of $606.42 million and -$1.28 billion in losses. Loss per share was -$6.42.
| Revenue | 606.42M |
| Gross Profit | 483.49M |
| Operating Income | -994.78M |
| Pretax Income | -1.27B |
| Net Income | -1.28B |
| EBITDA | -980.46M |
| EBIT | -994.78M |
| Loss Per Share | -$6.42 |
Full Income StatementBalance Sheet
The company has $1.43 billion in cash and $749.54 million in debt, giving a net cash position of $680.51 million or $3.15 per share.
| Cash & Cash Equivalents | 1.43B |
| Total Debt | 749.54M |
| Net Cash | 680.51M |
| Net Cash Per Share | $3.15 |
| Equity (Book Value) | 738.98M |
| Book Value Per Share | 3.45 |
| Working Capital | 1.33B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$935.01 million and capital expenditures -$32.56 million, giving a free cash flow of -$967.58 million.
| Operating Cash Flow | -935.01M |
| Capital Expenditures | -32.56M |
| Depreciation & Amortization | 14.31M |
| Net Borrowing | -4.93M |
| Free Cash Flow | -967.58M |
| FCF Per Share | -$4.48 |
Full Cash Flow StatementMargins
Gross margin is 79.73%, with operating and profit margins of -164.04% and -210.54%.
| Gross Margin | 79.73% |
| Operating Margin | -164.04% |
| Pretax Margin | -209.71% |
| Profit Margin | -210.54% |
| EBITDA Margin | -161.68% |
| EBIT Margin | -164.04% |
| FCF Margin | n/a |
Dividends & Yields
Insmed does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -21.32% |
| Shareholder Yield | -21.32% |
| Earnings Yield | -4.38% |
| FCF Yield | -3.32% |
Dividend DetailsAnalyst Forecast
The average price target for Insmed is $201.17, which is 49.08% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $201.17 |
| Price Target Difference | 49.08% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 24 |
| Revenue Growth Forecast (5Y) | 44.00% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
The last stock split was on March 3, 2011. It was a reverse split with a ratio of 1:10.
| Last Split Date | Mar 3, 2011 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
Insmed has an Altman Z-Score of 5.13 and a Piotroski F-Score of 4.
| Altman Z-Score | 5.13 |
| Piotroski F-Score | 4 |